The global high potency active pharmaceutical ingredients market is progressing at a CAGR of 9.90% from 2012 to 2018. The market was valued at US$9.1 bn in 2011 and is expected to reach US$17.5 bn by the end of 2018, according to a research report published by Transparency Market Research. The report, titled “High Potency Active Pharmaceutical Ingredients (HPAPIs) Market – Global Industry Analysis, Size, Growth, Share And Forecast 2012 – 2018”, is available on the company website.According to the report, the global HPAPI market is primarily driven by the global industry for oncology therapeutics. A growing prevalence of cancer and cancer-related symptoms has prompted a greater demand for HPAPIs. The report expects this trend to significantly fuel the global HPAPI market in the forecast period.
Download For Report Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=748
High potency active pharmaceutical ingredients are extremely beneficial in the treatment of illnesses such as different types of cancer, respiratory illnesses, and hormonal imbalances. It is due to this vast range of benefits that the global HPAPI market is showing a rapid rate of growth.Other drivers of the global HPAPI market are the impending patent expiration dates of top drugs, an increase in promotional activities enabled by regulatory bodies to focus on generic drugs, and a wider preference of insurance companies for generic drug makers over patented ones.One of the major trends in the global HPAPI market is the swift approval of high potency drug development projects.On the other hand, the report also elaborates on the restraining factors of the global HPAPI market, such as the issues with product differentiation by manufacturers of APIs, lack of standards of quality, and multiple regulatory loopholes.
The report segregates the global HPAPI market based on the categories of type of manufacturers, type of synthesis, type of market, and geography. The global HPAPI market is segmented based on synthesis into synthetic and biotech HPAPIs. From a manufacturing perspective, the market contains in-house and third-party manufacturers. According to the type of markets, HPAPIs are divided into the segments of innovative and generic HPAPIs. The report provides segment-specific details on each category and produces statistical proof of the growth curve and development rate of each segment.
Geographically, the global HPAPI market was dominated by North America in 2011. The report, however, states that Asia Pacific is the fastest growing region in the global HPAPI market, owing to the increase in demand for HPAPIs in China and India. Both countries are experiencing a rapid rate of industrialization and infrastructural improvements. Their economic growth is responsible for the high growth rate of the global HPAPI market.Key players in the global HPAPI market are Matrix Laboratories, Ltd., Boehringer Ingelheim Gmbh, Covidien Plc., Teva Pharmaceutical Industries Limited, Hospira Inc., Royal Dsm Nv, BASF SE, and Ranbaxy Laboratories Ltd.
Key segments of the Global HPAPI Market
By Type of Synthesis
By Type of Manufacturers
Captive or In-house manufacturers
Merchant or Third party manufacturers
By Type of Market
Major regions analyzed under this research report are:
Rest of the World
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.